| 产品描述： | SIRT1 选择性抑制剂 | 活化剂 | 调节剂;SIRT1 Selective Inhibitors | Activators | Modulators;;InformationSRT2183 is a small-molecule activator of the sirtuin subtypeSIRT1, currently being developed by Sirtris Pharmaceuticals.TargetsSIRT1In vitroSRT2183 is potent with growth arrest and apoptosis induced at doses ranging from 1-20 μM. SRT2183 treatment leads to increased mRNA levels of pro-apoptosis, growth arrest, and DNA damage response genes. SRT1720, SRT2183, SRT1460, and resveratrol exhibit multiple off-target activities against receptors, enzymes, transporters, and ion channels. They are not direct activators of SIRT1. SRT2183 has little or no effect on SIRT1 deacetylating activity with native full-length substrates. SRT2183 activates AMPK, increases Sirt1 expression and decreases RelA/p65 lysine310 acetylation, critical for NF-κB activation, and an established Sirt1 target and inhibits RANKL-induced osteoclast generation and resorptive capacity in bone marrow macrophages.Cell Research(from reference)Cell lines：Bone-marrow derived macrophages(BMMs) Concentrations：1μM Incubation Time：72 h |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京